-
STAT News – Biotech3 months agoSTAT+: Merck to buy Terns Pharmaceuticals in $6.7B deal
Merck said Wednesday that it intends to buy Terns Pharmaceuticals, the developer of a promising leukemia treatment, for $6.7 billion. The deal values Terns at $53...
-
Uncategorized3 months agoTwelve startups to showcase at SLAS Europe 2026
SLAS, the Society of Laboratory Automation and Screening, has introduced the 12 companies selected for the Innovation AveNEW programme at SLAS Europe 2026 Conference and Exhibition,...
-
Endpoints News3 months ago
Maze meets own expectations in Phase 2 kidney disease trial in the same arena as Vertex
Maze Therapeutics unveiled positive mid-stage data for its genetic kidney disease drug that could spell major competition for Vertex Pharmaceuticals’ program that has the same target....
-
Fierce Biotech3 months ago
After ph. 2 readout, analysts herald ‘best-in-class potential’ for Maze kidney candidate as stock plummets
Maze Therapeutics has revealed topline phase 2 data for its lead kidney disease candidate that has analysts heralding its “best-in-class potential.” But many investors were racing...
-
Endpoints News3 months ago
Merck to buy Terns for $6.7B, taking a leukemia drug that could challenge Novartis’ Scemblix
Merck is looking to further solidify its oncology pipeline via a $6.7 billion cash acquisition of Terns Pharmaceuticals and its investigational treatment for chronic myeloid leukemia....
-
Fierce Biotech3 months ago
Takeda targets $1.3B in cost savings in further restructuring
Takeda is setting the stage for a sweeping new round of restructuring, aiming to streamline operations to bankroll upcoming drug launches and late-stage pipeline development.
-
Fierce Biotech3 months ago
Endogenex nets $50M to carry intestinal diabetes procedure to the FDA
The fundraising comes after clinical results showed its system met safety goals and led to metabolic improvements in HbA1c, fasting glucose levels and body weight.
-
Endpoints News3 months ago
Gilgamesh’s psychedelics pipeline gets $60M backing after AbbVie deal
Investors have pumped $60 million into Gilgamesh Pharma to test a handful of psychedelics and other experimental neuroscience medicines that the biotech hasn’t yet promised to...
-
GEN – Genetic Engineering & Biotechnology News3 months ago
Genomic Mapping of E. coli Capsules Identifies High-Risk Types for Vaccines
A sweeping genomic survey is offering the clearest picture yet of how Escherichia coli uses its protective capsule to evade the immune system—and which capsule types...
-
Uncategorized3 months agoLilly’s triple agonist significantly reduces A1C and weight
Eli Lilly has announced positive topline results from TRANSCEND-T2D-1, a Phase III clinical trial evaluating the efficacy and safety of retatrutide, an investigational first-in-class GIP, GLP-1...
Beyond sunshine: Iberia’s biotech moment has arrived with developing capital networks
Laser‑Driven Phase Contrast Enhances Cryo‑EM Resolution of Small Proteins
